Daisuke Kotani, MD, Ph.D 小谷 大輔· @DaisukeKotani · X·· 2 天前评分70
正文
暂无中文译文，显示英文原文。
#ESMO26
G-HOPE-001
@myESMO @OncoAlert
914 浏览 · 15 赞 · 5 转发 · 0 回复
会议摘要
LBA77按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.org#ESMO26 | LBA77 G-HOPE-001: Ph3 Arcotatug tavatecan (CLDN-ADC) vs SoC in 3L+ CLDN18.2+ GEA ▪️PFS: 5.5 vs 2.9 mo, HR 0.47, p<0.0001 ▪️OS: 9.9 vs 7.4 mo, HR 0.63 ▪️ORR: 23.6% vs 5.3% @myESMO @OncoAlert在 X 查看被引用的帖子
来源：Daisuke Kotani, MD, Ph.D 小谷 大輔 · x.com